We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

85 hedge funds and large institutions have $294M invested in Kalaris Therapeutics in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

168% more capital invested

Capital invested by funds: $110M → $294M (+$184M)

55% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 22

48% more call options, than puts

Call options by funds: $267K | Put options by funds: $180K

1% more funds holding

Funds holding: 84 → 85 (+1)

6% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 16

0.13% less ownership

Funds ownership: 1.87% → 1.74% (-0.13%)

Holders
85
Holders Change
+1
Holders Change %
+1.19%
% of All Funds
1.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
34
Reduced
22
Closed
16
Calls
$267K
Puts
$180K
Net Calls
+$87K
Net Calls Change
-$42K

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$22M
2
Alkeon Capital Management
Alkeon Capital Management
New York
+$14.7M
3
RG
Redmile Group
California
+$7.35M
4
GC
GMT Capital
Georgia
+$5.88M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$5.85M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$1.13M
2
Goldman Sachs
Goldman Sachs
New York
-$375K
3
Barclays
Barclays
United Kingdom
-$367K
4
Two Sigma Investments
Two Sigma Investments
New York
-$304K
5
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$293K
Name Holding Trade Value Shares
Change 		Change in
Stake
Carson Wealth (CWM LLC)
76
Carson Wealth (CWM LLC)
Nebraska
$6K – – –
Simplex Trading
77
Simplex Trading
Illinois
$4K +$3.9K +25 New
Royal Bank of Canada
78
Royal Bank of Canada
Ontario, Canada
$3K -$623 -4 -19%
QCG
79
Quadrant Capital Group
Ohio
$3K +$2.34K +15 New
LC
80
Lindbrook Capital
California
$3K +$2.65K +17 New
Daiwa Securities Group
81
Daiwa Securities Group
Japan
$2K – – –
S
82
SignatureFD
Georgia
$2K +$1.56K +10 New
IA
83
IFP Advisors
Florida
$1K – – –
MPWT
84
MassMutual Private Wealth & Trust
Connecticut
$1K +$467 +3 New
Two Sigma Investments
85
Two Sigma Investments
New York
– -$304K -3,393 Closed
HF
86
HRT Financial
New York
– -$169K -1,893 Closed
E
87
Ergoteles
New York
– -$111K -1,235 Closed
DekaBank Deutsche Girozentrale
88
DekaBank Deutsche Girozentrale
Germany
– -$84K -935 Closed
Millennium Management
89
Millennium Management
New York
– -$68K -762 Closed
Squarepoint
90
Squarepoint
New York
– -$66K -738 Closed
TI
91
Trexquant Investment
Connecticut
– -$59K -660 Closed
HSBC Holdings
92
HSBC Holdings
United Kingdom
– -$56K -641 Closed
VF
93
Virtu Financial
New York
– -$55K -614 Closed
JF
94
Jump Financial
Illinois
– -$52K -583 Closed
OQS
95
Occudo Quantitative Strategies
Florida
– -$48K -532 Closed
DU
96
Delphia (USA)
Ontario, Canada
– -$44K -491 Closed
CC
97
Corton Capital
Ontario, Canada
– -$41K -456 Closed
PHK
98
Point72 Hong Kong
Hong Kong
– -$18K -202 Closed
PFS
99
Prospera Financial Services
Texas
– -$9K -103 Closed
Federated Hermes
100
Federated Hermes
Pennsylvania
– -$1K -6 Closed
1 2 3
4
5

KLRS Hedge Fund Activity: Q3 2022 in Review

85 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2022, worth a combined $294M — up 168% from $110M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KLRS positions and 16 closed out — a net gain of 1 holder — while 34 added to existing stakes and 22 trimmed.

The largest buyer was Artal Group, adding an estimated $22M. The largest seller was JP Morgan Chase, cutting an estimated $1.13M.

  • 85 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2022, up from 84 in Q2 2022.
  • Funds reported $294M of Kalaris Therapeutics stock for Q3 2022, up 168% quarter-over-quarter.
  • 17 funds opened new Kalaris Therapeutics positions in Q3 2022 and 16 closed out, a net change of +1 holder.
  • The largest Kalaris Therapeutics buyer in Q3 2022 was Artal Group, an estimated $22M added.
  • The largest Kalaris Therapeutics seller in Q3 2022 was JP Morgan Chase, an estimated $1.13M sold.

Based on aggregated 13F filings for Q3 2022.